{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:35:24Z","timestamp":1790969724447,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Data on long-term treatment regimens for preventing bone mineral density (BMD) loss that occurs after denosumab (Dmab) withdrawal are scarce. Our aim was to evaluate the long-term changes (12\u201336\u00a0months) in BMD and bone turnover markers in a group of postmenopausal women who had been treated with Dmab and received subsequent treatment with bisphosphonates. Secondary objectives were to evaluate factors associated with BMD loss, to compare the BMD change in patients who received oral vs intravenous bisphosphonates, and to assess the frequency of fragility fractures after Dmab discontinuation. The clinical data of 54 patients, 26 of whom had clinical and DXA assessments at 36\u00a0months, were analyzed. After 12\u00a0months, the mean LS BMD had decreased by 2.8% (\u00b15.0), FN BMD by 1.9% (\u00b15.8), and TH BMD by 1.9% (\u00b13.7). After 36\u00a0months, LS BMD had decreased by 3.7% (\u00b16.7), FN BMD by 2.5% (\u00b17.1), and TH BMD by 3.6% (\u00b15.2). C-terminal cross-linked telopeptide of type I collagen significantly increased during the first 12\u00a0months after Dmab withdrawal but then decreased at 36\u00a0months. BMD loss at 12\u00a0months was higher in patients with more than 30\u00a0months of Dmab treatment, but this difference was only statistically significant at FN (\u22123.3% vs \u22120.3%, P\u2009=\u2009.252 at LS, \u22123.3% vs 0.3%, P\u2009=\u2009.033 at FN, and \u22122.1% vs 0.9, P\u2009=\u2009.091 at TH). There were no statistically significant differences regarding the change in BMD at 12 and 36\u00a0months between oral and intravenous treatment. Seven patients suffered incidental vertebral fractures (clinical vertebral fractures: n\u2009=\u20096, morphometric fractures: n\u2009=\u20091) three of which were multiple. None of these patients were treated following international or institutional guidelines or recommendations. In summary, our study suggests that bisphosphonates can help maintain BMD for 36\u00a0months after Dmab discontinuation.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziae044","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T15:49:41Z","timestamp":1714405781000},"source":"Crossref","is-referenced-by-count":8,"title":["Three-year effect of bisphosphonates on bone mineral density after denosumab withdrawal: observations from a real-world study"],"prefix":"10.1093","volume":"8","author":[{"given":"Vanina","family":"Farias","sequence":"first","affiliation":[{"name":"Instituto de Diagn\u00f3stico e Investigaciones Metab\u00f3licas (IDIM) , ZP 1012, Buenos Aires , Argentina"},{"name":"C\u00e1tedra de Osteolog\u00eda y Metabolismo Mineral, Universidad del Salvador , ZP 1012, Buenos Aires , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-7145","authenticated-orcid":false,"given":"Fernando","family":"Jerkovich","sequence":"additional","affiliation":[{"name":"Instituto de Diagn\u00f3stico e Investigaciones Metab\u00f3licas (IDIM) , ZP 1012, Buenos Aires , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Morej\u00f3n","family":"Barrag\u00e1n","sequence":"additional","affiliation":[{"name":"C\u00e1tedra de Osteolog\u00eda y Metabolismo Mineral, Universidad del Salvador , ZP 1012, Buenos Aires , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Pereyra","sequence":"additional","affiliation":[{"name":"C\u00e1tedra de Osteolog\u00eda y Metabolismo Mineral, Universidad del Salvador , ZP 1012, Buenos Aires , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Gonz\u00e1lez","family":"Pernas","sequence":"additional","affiliation":[{"name":"Instituto de Diagn\u00f3stico e Investigaciones Metab\u00f3licas (IDIM) , ZP 1012, Buenos Aires , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Abdala","sequence":"additional","affiliation":[{"name":"Instituto de Diagn\u00f3stico e Investigaciones Metab\u00f3licas (IDIM) , ZP 1012, Buenos Aires , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Longobardi","sequence":"additional","affiliation":[{"name":"Instituto de Diagn\u00f3stico e Investigaciones Metab\u00f3licas (IDIM) , ZP 1012, Buenos Aires , Argentina"},{"name":"C\u00e1tedra de Osteolog\u00eda y Metabolismo Mineral, Universidad del Salvador , ZP 1012, Buenos Aires , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9397-1847","authenticated-orcid":false,"given":"Mar\u00eda Bel\u00e9n","family":"Zanchetta","sequence":"additional","affiliation":[{"name":"Instituto de Diagn\u00f3stico e Investigaciones Metab\u00f3licas (IDIM) , ZP 1012, Buenos Aires , Argentina"},{"name":"C\u00e1tedra de Osteolog\u00eda y Metabolismo Mineral, Universidad del Salvador , ZP 1012, Buenos Aires , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"issue":"Suppl 1","key":"2024051906110183500_ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"5","key":"2024051906110183500_ref2","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological Management of Osteoporosis in Postmenopausal Women: an Endocrine Society* Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024051906110183500_ref3","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological Management of Osteoporosis in postmenopausal women: an Endocrine Society guideline Update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024051906110183500_ref4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.ogx.0000363236.41902.96","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"64","author":"Cummings","year":"2009","journal-title":"Obstet Gynecol Surv"},{"issue":"7","key":"2024051906110183500_ref5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2024051906110183500_ref6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"issue":"11","key":"2024051906110183500_ref7","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"key":"2024051906110183500_ref8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"issue":"1","key":"2024051906110183500_ref9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024051906110183500_ref10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of Zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of Bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024051906110183500_ref11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"2024051906110183500_ref12","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"S\u00f8lling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024051906110183500_ref13","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"7","key":"2024051906110183500_ref14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"S\u00f8lling","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024051906110183500_ref15","doi-asserted-by":"crossref","first-page":"E4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2024051906110183500_ref16","doi-asserted-by":"crossref","first-page":"115478","DOI":"10.1016\/j.bone.2020.115478","article-title":"The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis","volume":"138","author":"Makras","year":"2020","journal-title":"Bone [Internet]"},{"issue":"12","key":"2024051906110183500_ref17","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2024051906110183500_ref18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116498","article-title":"Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting","volume":"163","author":"Everts-Graber","year":"2022","journal-title":"Bone"},{"issue":"7","key":"2024051906110183500_ref19","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cell.2021.03.010","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"issue":"5","key":"2024051906110183500_ref20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","article-title":"Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone","volume":"19","author":"Ferrari","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2024051906110183500_ref21","doi-asserted-by":"crossref","first-page":"115830","DOI":"10.1016\/j.bone.2020.115830","article-title":"Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study","volume":"144","author":"Everts-Graber","year":"2021","journal-title":"Bone"},{"issue":"3","key":"2024051906110183500_ref22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziae044\/57398800\/ziae044.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/8\/6\/ziae044\/57727913\/ziae044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/8\/6\/ziae044\/57727913\/ziae044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T02:15:02Z","timestamp":1716084902000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziae044\/7664203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziae044","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2024,4,30]]},"article-number":"ziae044"}}